secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001157523-23-001700
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q3 net loss $25.7M; starts pivotal GRAND CANYON study for EDG-5506
---------------------------------------------------------------------------

- Cash and equivalents ~$290M; Q3 net loss $25.7M ($0.41/share) vs $21.5M prior quarter.
- Initiated GRAND CANYON, global pivotal study of EDG-5506 in Becker MD, aiming for ~120 patients.
- LYNX Phase 2 trial for Duchenne expanding with new cohort; interim data expected H1 2024.
- Phase 1 trial of EDG-7500 for hypertrophic cardiomyopathy under way; Phase 1b planned H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323001700/0001157523-23-001700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752323001700/a53795839.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer